Ocugen presents clinical data with significant LLVA improvement (p=0.005) at Year 1 in retinal disease study

Ocugen, Inc.

Mean change in LLVA from baseline improved in treated eye vs untreated (p=0.005 at Year 1).
75% of patients met responder criterion (6/8) at measured timepoints.
Mean total atrophy area change at Month 12 showed trend favoring treated eye (p=0.055).
Mean BCVA (ETDRS) change from baseline reported up to Month 12.
Presentation includes Year 1 and Year 2 data from the clinical trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.